18/08/2008
Following on from shareholder enquiries we would like to stress to you that ColostrininTM may be one of the first compounds with the potential to impact on both tau tangles and beta-amyloid plaques. These are two key pathologies of Alzheimer’s disease. Some confusion arose over why we had mentioned in our press release on 12th August Rember the trade mark of TauRx. We did this because in the previous weeks there had been some significant publicity suggesting efficacy of Rember in Alzheimer’s disease because of its impact on tau tangles. We were pointing out that our compound deals with two and not just one key pathology of Alzheimer’s.
If you wish to discuss this further please contact ReGen head office on 020 7153 4920.
Percy Lomax
Executive Chairman